Buy & Sell DigitalOcean Holdings Inc (DOCN) – DigitalOcean Holdings Inc Price Today
Aura AI Summary
Key Stats
- $17.57BMarket Cap
- TechnologySector
- -18.4%3M Drawdown
- $18.13BEnterprise Value
- -Dividend Yield
- 27% Buy | 73% SellTrading Activity
- 41 daysTypical Hold Time
DigitalOcean Holdings Inc (DOCN) is currently valued at a market capitalization of $17.57B, with an enterprise value of $18.13B. Over the past 52 weeks, DigitalOcean Holdings Inc has traded between a low of $25.74 and a high of $180.58, highlighting its annual price range. Over the past three months, DigitalOcean Holdings Inc has recorded a drawdown of -18.4%, reflecting recent price volatility. On average, investors hold DigitalOcean Holdings Inc for approximately 41 days, indicating typical investor behavior on the platform.
About DigitalOcean Holdings Inc
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and other countries.
Most Recent News
Global Initiative on Loneliness and Connection hosts forum to tackle social division and loneliness worldwide
The Global Initiative on Loneliness and Connection (GILC) convened the 2026 Global Connection Forum on June 17 to address the growing public health crisis of loneliness and social isolation, which contribute to serious health risks and societal divis...

Metastatic prostate cancer market to grow strongly through 2036 with new targeted therapies emerging.
The metastatic prostate cancer market is shifting from traditional hormone therapies to precision, biomarker-driven treatments, including novel PARP inhibitors and PSMA-targeted radioligand therapies. The market, valued at $11.5 billion in 2025 in ma...

Over 30 pharma companies race to develop 35+ lupus nephritis drugs, advancing treatment options globally.
The lupus nephritis clinical trial landscape is rapidly expanding with more than 30 pharmaceutical companies developing over 35 drugs targeting this serious autoimmune kidney condition. Key players like Novartis, Simcere, and Regeneron are advancing ...
